Background Cost-effectiveness analyses (CEAs) on prevention of non-communicable
diseases (NCDs) are necessary to guide decision makers to allocate scarce healthcare …

Background Several studies have shown the cost-effectiveness of direct oral anticoagulants
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …

Background Direct oral anticoagulants (DOACs) are commonly used to prevent stroke and
systemic embolism in patients with atrial fibrillation (AF). However, studies into their …

Aims This study aimed to evaluate the prescriber compliance to the approved labels of direct
oral anticoagulants (DOACs) and impact of appropriateness of dosing on clinical outcomes …

Background This study aimed to assess the cost-effectiveness of non-vitamin K antagonist
oral anticoagulants (NOACs) in comparison with warfarin using data from real practice …

Objectives Dabigatran has a better safety profile and requires less monitoring, but is costlier
than warfarin. This study evaluated the cost-utility of dabigatran relative to warfarin for …

Objectives Several studies have evaluated the economic evaluation of a group of
medications known as novel oral anticoagulant drugs (NOACs) in recent years. The aim of …

Background Asian population are at increased risk of bleeding during the warfarin treatment,
so the recommended optimal international normalized ratio (INR) level may be lower in …

Background Atrial fibrillation (AF) can lead to a significant health and economic burden to
society. This study aimed to assess the net budget impact of direct-acting oral anticoagulants …

Цель. Сравнить по фармакоэкономическим показателям эффективность применения
прямых пероральных антикоагулянтов (ПОАК) у пациентов с неклапанной …